Tests toripalimab with chemotherapy before surgery for sinus cancer
Tests an immunotherapy drug with chemotherapy before surgery in adults with sinus cancer.
Key facts
- Who runs it
- Dana-Farber Cancer Institute
- Where
- Boston, United StatesSee the 2 sites
- Trial code
- Registry title
- Toripalimab With Chemotherapy for Sinus Cancer
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 20 people, planned
- Started
- 17 Jun 2025
- Expected to end
- 1 Feb 2029
- Type of study
- Interventional, 3 groups
- Treatments tested
- Toripalimab
- Carboplatin
- Docetaxel
- Radiation Therapy
- Cisplatin
- Record updated
- 31 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced cancer of the nasal cavity or sinuses (squamous cell carcinoma or sinonasal undifferentiated carcinoma) that can be treated with surgery. Toripalimab with chemotherapy is given before surgery.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Advanced squamous cell carcinoma or sinonasal undifferentiated carcinoma of the nasal cavity or paranasal sinus, clinical stage T2 N1-3, T3 or T4 (stage III, IVA or IVB). Squamous cell carcinoma must be resectable. Sinonasal undifferentiated carcinoma can be operable or borderline resectable.
- Earlier treatment
- People who have had an anti-PD-1/L1 drug, or another drug aimed at a T-cell receptor, before cannot join. A live vaccine within 30 days before the first dose is not allowed.
Main reasons for not taking part
- Other cancer types of the nose or sinuses, such as melanoma, lymphoma or sinonasal neuroendocrine carcinoma
- Cancer that cannot be operated on, or that has spread to distant parts of the body (M1 or IVC)
- Active autoimmune disease needing treatment in the past 6 months, or immune deficiency
- Past solid organ or allogeneic tissue transplant
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Participants must have histologically or cytologically confirmed locoregionally advanced nasal cavity or paranasal sinus cancer including the following histologic subtypes: squamous cell carcinoma (SCC) of any morphologic variation: verrucous, papillary, basaloid, spindle cell, and adenosquamous; or sinonasal undifferentiated carcinoma (SNUC)
- Participants with SCC should have resectable disease at baseline per the discretion of the treating surgical oncologist(s). *Participants with SNUC can have operable or borderline resectable (definition: resection would been morbid requiring extensive surgery and would have chances of incomplete gross total resection) disease as judged by the treating surgical oncologist(s)
- Participants must have clinical stage disease as defined below using the 8th (2017) edition of the tumor, node, metastasis (TNM) staging system by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC):; T2, N1-3 III; T3, any N III, IVA, IVB; T4, any N IVA, IVB
- Participants must be willing to provide blood and tissue pre-treatment and at the time of surgery for pathologic and correlative analyses
- Age 18 years or older at the time of informed consent
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Participants must have adequate organ and marrow function as defined below:; Absolute neutrophil count ≥1000/mcL; Platelets ≥100; Total bilirubin ≤institutional upper limit of normal (ULN); AST(SGOT) / ALT (SGPT) ≤3x ULN; Creatinine ≤institutional ULN or GFR of ≥50 mL/min/1.73 m2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m2
- Women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Contraception use should be maintained until at least 6 months after the last dose of chemotherapy for females and 3 months for males. In addition, contraception use should continue until 4 months after last dose of toripalimab for both males and females
- Ability to understand and the willingness to sign a written informed consent document
Who cannot take part
- Has received prior therapy with an anti-PD-1/L1 agent or any other agent directed to another stimulatory or co-inhibitory T-cell receptor
- Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug. Non-live vaccines are permitted
- Carries a diagnosis of immunodeficiency or is receiving chronic systemic corticosteroid therapy (in doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug
- Participants with nasal cavity or paranasal sinus malignancies demonstrating histologies other than SCC or SNUC in the opinion of the reviewing pathologist. Excluded subtypes include: angiosarcomas, rhabdomyosarcomas, lymphomas, olfactory neuroblastomas (esthesioneuroblastomas), melanomas, and meningiomas among others. SNEC or sinonasal neuroendocrine carcinoma is not permitted
- Participants with unresectable or inoperable disease as judged by the treating surgical oncologist(s)
- Participants with known distant metastatic disease (M1 or IVC)
- Has a known additional malignancy that is progressing or has required active treatment within the past 2 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded. Exceptions may be permitted at the discretion of the overall Sponsor-Investigator
- Has an active autoimmune disease that has required systemic treatment in past 6 months (with use of a disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is permitted
- Has a history of (non-infectious) pneumonitis or interstitial lung disease that required steroids or has current pneumonitis or interstitial lung disease
- Has a known history of active Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority
- Has a history of allogeneic tissue or solid organ transplant
- Has a known history of human immunodeficiency virus (HIV) infection that is uncontrolled. No HIV testing is required unless mandated by local health authority. Patients with well controlled HIV may be eligible if their CD4 T cell count is favorable and their HIV viral load is undetectable
- Women who are pregnant or breastfeeding
This trial is currently available in United States.
- Brigham and Women's HospitalBoston, United StatesContact: Kartik Sehgal, MDTaking people
- Dana-Farber Cancer InstituteBoston, United StatesContact: Kartik Sehgal, MDTaking people
About the trial
What the trial wants to find out
The aim of this research study is to evaluate the effectiveness and safety of a combination of immunotherapy, using a drug called toripalimab, with chemotherapy drugs, Carboplatin and Docetaxel, as a possible treatment before surgery for sinonasal cancers.
Read full original descriptionShow less
The names of the study drugs used in this research study are:
* Toripalimab (a type of monoclonal antibody) * Carboplatin (a type of antineoplastic agent) * Docetaxel (a type of antineoplastic agent) * Cisplatin (a type of antineoplastic agent)
The 3 groups in the trial
- Arm 1: Toripalimab and Docetaxel Plus Carboplatin (TCD)Treatment being tested
* Baseline visit with imaging * Cycles 1 and 2 (21 day cycles) * Day 1: Predetermined dose of Toripalimab 1x daily * Day 1: Chemotherapy: predetermined dose of Docetaxel 1x daily and Carboplatin 1x daily * Tumor assessment by imaging * Surgical resection of tumor
Treatment: Toripalimab, Carboplatin, and Docetaxel
- Arm 2: Post Operative Radiation Therapy + ToripalimabTreatment being tested
After pathology assessment, participants with a pathological treatment response of 2 will be assigned radiation therapy per standard practice guidelines and predetermined dose of Toripalimab 1x every 3 weeks for up to 8 cycles (21 day cycles). -Follow up: every 3 months for 1 year. Imaging at 3 months
Treatment: Toripalimab and Radiation Therapy
- Arm 3: Post Operative Radiation Therapy With or Without ChemotherapyTreatment being tested
After pathology assessment, participants with a pathological treatment response of 2 or less will be assigned standard radiation therapy with or without standard of care Cisplatin-based chemotherapy as recommended per treatment team and standard practice guidelines. -Follow up: every 3 months for 1 year. Imaging at 3 months
Treatment: Radiation Therapy and Cisplatin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Perioperative Chemoimmunotherapy With Toripalimab for Sinonasal Cancer
- Plain-language title
- Tests toripalimab with chemotherapy before surgery for sinus cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 31 August 2026